A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix

A southwest oncology group trial

Geoffrey R. Weiss, Stephanie Green, Edward V. Hannigan, John G. Boutselis, Earl A. Surwit, Darryl L. Wallace, David S Alberts

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix. Cisplatin was administered at a dosage of 100 mg/m2 iv bolus and 5-fluorouracil was cotinuously infused iv at a dosage of 1000 mg/m2/day for 4 days. In an effort to determine whether the toxicities of 5-fluorouracil could be ameliorated by coadministration of allopurinol, patients were randomized to receive allopurinol, 900 mg orally, an odd or even courses of therapy beginning 5 days before 5-fluorouracil administration and continuing until conclusion of the infusion. Fifty-two eligible patients received 177 evaluable courses of treatment. The overall response rate was 28% (8 complete responses and 6 partial responses). Toxicity was confined to nausea and vomiting (81% of courses), anemia (47%), leukopenia (37%), oral mucositis (15%), diarrhea (6%), and thrombocytopenia (4%). Allopurinol produced no improvement in treatment-related toxicities. Allopurinol did not permit substantial increases in 5-fluorouracil dosage.

Original languageEnglish (US)
Pages (from-to)354-358
Number of pages5
JournalGynecologic Oncology
Volume37
Issue number3
DOIs
StatePublished - 1990

Fingerprint

Allopurinol
Cervix Uteri
Fluorouracil
Cisplatin
Carcinoma
Stomatitis
Leukopenia
Nausea
Esophagus
Vomiting
Anemia
Squamous Cell Carcinoma
Diarrhea
Neck
Therapeutics
Head
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix : A southwest oncology group trial. / Weiss, Geoffrey R.; Green, Stephanie; Hannigan, Edward V.; Boutselis, John G.; Surwit, Earl A.; Wallace, Darryl L.; Alberts, David S.

In: Gynecologic Oncology, Vol. 37, No. 3, 1990, p. 354-358.

Research output: Contribution to journalArticle

Weiss, Geoffrey R. ; Green, Stephanie ; Hannigan, Edward V. ; Boutselis, John G. ; Surwit, Earl A. ; Wallace, Darryl L. ; Alberts, David S. / A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix : A southwest oncology group trial. In: Gynecologic Oncology. 1990 ; Vol. 37, No. 3. pp. 354-358.
@article{4eb897a8ad1142deb7ada1083bfd7833,
title = "A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: A southwest oncology group trial",
abstract = "On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix. Cisplatin was administered at a dosage of 100 mg/m2 iv bolus and 5-fluorouracil was cotinuously infused iv at a dosage of 1000 mg/m2/day for 4 days. In an effort to determine whether the toxicities of 5-fluorouracil could be ameliorated by coadministration of allopurinol, patients were randomized to receive allopurinol, 900 mg orally, an odd or even courses of therapy beginning 5 days before 5-fluorouracil administration and continuing until conclusion of the infusion. Fifty-two eligible patients received 177 evaluable courses of treatment. The overall response rate was 28{\%} (8 complete responses and 6 partial responses). Toxicity was confined to nausea and vomiting (81{\%} of courses), anemia (47{\%}), leukopenia (37{\%}), oral mucositis (15{\%}), diarrhea (6{\%}), and thrombocytopenia (4{\%}). Allopurinol produced no improvement in treatment-related toxicities. Allopurinol did not permit substantial increases in 5-fluorouracil dosage.",
author = "Weiss, {Geoffrey R.} and Stephanie Green and Hannigan, {Edward V.} and Boutselis, {John G.} and Surwit, {Earl A.} and Wallace, {Darryl L.} and Alberts, {David S}",
year = "1990",
doi = "10.1016/0090-8258(90)90366-S",
language = "English (US)",
volume = "37",
pages = "354--358",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix

T2 - A southwest oncology group trial

AU - Weiss, Geoffrey R.

AU - Green, Stephanie

AU - Hannigan, Edward V.

AU - Boutselis, John G.

AU - Surwit, Earl A.

AU - Wallace, Darryl L.

AU - Alberts, David S

PY - 1990

Y1 - 1990

N2 - On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix. Cisplatin was administered at a dosage of 100 mg/m2 iv bolus and 5-fluorouracil was cotinuously infused iv at a dosage of 1000 mg/m2/day for 4 days. In an effort to determine whether the toxicities of 5-fluorouracil could be ameliorated by coadministration of allopurinol, patients were randomized to receive allopurinol, 900 mg orally, an odd or even courses of therapy beginning 5 days before 5-fluorouracil administration and continuing until conclusion of the infusion. Fifty-two eligible patients received 177 evaluable courses of treatment. The overall response rate was 28% (8 complete responses and 6 partial responses). Toxicity was confined to nausea and vomiting (81% of courses), anemia (47%), leukopenia (37%), oral mucositis (15%), diarrhea (6%), and thrombocytopenia (4%). Allopurinol produced no improvement in treatment-related toxicities. Allopurinol did not permit substantial increases in 5-fluorouracil dosage.

AB - On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix. Cisplatin was administered at a dosage of 100 mg/m2 iv bolus and 5-fluorouracil was cotinuously infused iv at a dosage of 1000 mg/m2/day for 4 days. In an effort to determine whether the toxicities of 5-fluorouracil could be ameliorated by coadministration of allopurinol, patients were randomized to receive allopurinol, 900 mg orally, an odd or even courses of therapy beginning 5 days before 5-fluorouracil administration and continuing until conclusion of the infusion. Fifty-two eligible patients received 177 evaluable courses of treatment. The overall response rate was 28% (8 complete responses and 6 partial responses). Toxicity was confined to nausea and vomiting (81% of courses), anemia (47%), leukopenia (37%), oral mucositis (15%), diarrhea (6%), and thrombocytopenia (4%). Allopurinol produced no improvement in treatment-related toxicities. Allopurinol did not permit substantial increases in 5-fluorouracil dosage.

UR - http://www.scopus.com/inward/record.url?scp=0025340840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025340840&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90366-S

DO - 10.1016/0090-8258(90)90366-S

M3 - Article

VL - 37

SP - 354

EP - 358

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -